Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CT103A elicits responses after prior CAR T-cell relapse

Key clinical point: CT103A, a chimeric antigen receptor (CAR) T-cell therapy, produced responses in patients with relapsed/refractory multiple myeloma, including those who had previously received CAR T-cell therapy.

Major finding: CT103A produced a 100% response rate in patients with heavily pretreated multiple myeloma, and three of four patients who had failed a prior CAR T-cell therapy achieved a stringent complete response after CT103A.

Study details: Phase 0 study of 18 patients

Disclosures: The study was funded by Nanjing Iaso Biotherapeutics. Dr. Li did not disclose any conflicts of interest.


Li C et al. IMW 2019, Abstract OAB-033.